4:47 PM
Jul 05, 2017
 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc. spun out its histone deacetylase (HDAC) assets into Regenacy prior to its acquisition by Celgene Corp. (NASDAQ:CELG).

Dermatology play Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) named David Domzalski CEO. He succeeds...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >